Developer docs
API playgroundTry for free, no card

Search company profiles

Beats Medical

Full company profile

uuid0009pgp

Namestring
Beats Medical
Legal namestring
Beats Therapeutics Limited
Company typeenum
Private
Founded yearint
2013
Descriptiontext

Beats Medical Limited (trading as Beats Medical, incorporated as Beats Therapeutics Limited, Ireland company number 619940) is a Dublin-based digital therapeutics company founded in 2013 by chartered physiotherapist Dr Ciara Clancy. The company develops the Colbolt© platform, a patented AI/ML-powered DTx architecture that delivers objective digital assessments and tailored therapies via smartphone applications for central nervous system (CNS) and rare conditions, using built-in sensors (accelerometer, gyroscope, microphone) without additional hardware. The product portfolio spans four consumer-facing apps — the prescription-only Parkinson's app (mobility, speech, dexterity), Dystant Galaxy for pediatric Dyspraxia, Wonders Cape for child wellbeing, and the Branches clinical research app — plus B2B services including digital consulting, observational study solutions, clinical trial solutions, and data insights powered by Colbolt.

The company operates a dual-track go-to-market: (1) B2B pharma, where Colbolt is white-labeled or co-branded into the clinical pipelines of Top 10 Global Pharma companies from pre-clinical through commercialization; and (2) direct-to-consumer subscriptions (€30.40/month or €330/year) via iOS and Android app stores with a 14-day free trial, supplemented by insurance reimbursement through Vhi (Ireland's largest private health insurer, covering 1.2M+ customers for the Dyspraxia app). Revenue streams comprise consumer subscription recurring fees, pharma platform licensing and royalties, digital consulting professional services, and managed insurance reimbursement. Beats Medical is ISO 13485 certified, employs 1-10 people, and operates from Sandyford, Dublin, with commercial users across 30+ countries.

Short descriptiontext

Beats Medical develops the Colbolt© AI/ML digital therapeutics platform that delivers objective assessments and tailored therapies via smartphone apps for CNS and rare conditions, serving pharmaceutical companies (clinical trials), individual Parkinson's and Dyspraxia patients via subscription apps, and insurers through Vhi reimbursement.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersDublin, Ireland
HQ citystring
Dublin
HQ countrystring
Ireland
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
digital therapeutics, clinical trial technology, Parkinson's disease apps, digital biomarkers, mobile health assessments
Industry3 codes
PRIMARYHLACANAH
Therapeutic Companion Apps (Drug-Device-Digital Combination)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLACAOAL
Decentralized/Hybrid Trial Enablement (DCT) Platforms
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Trials & Research Informatics (eCOA/ePRO/EDC)
SECONDARYHLAGAJAM
Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
NAICS code3 codes
  • Other Scientific and Technical Consulting Services54169
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Scientific Research and Development Services5417
SIC code2 codes
  • Electromedical & Electrotherapeutic Apparatus3845
  • Surgical & Medical Instruments & Apparatus3841
Product category
Digital Therapeutics
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model5 records
1Consumer App Subscriptions (Parkinson's)
TypeSubscription Recurring
Description

Direct-to-consumer subscription for the Beats Medical Parkinson's Therapy app. Two tiers: Monthly subscription at €30.40/month (daily charge of €1.00) paid by direct debit; Annual subscription at €330/year (€27.50/month equivalent). Subscriptions auto-renew annually. 14-day free trial available for conversion. Services include daily tailored walking metronome therapy, speech exercises, dexterity exercises, calendar medication reminders, and monthly progress reports. The app is prescription-only and intended for home use.

beatsmedical.com
2Consumer App Subscriptions (Dyspraxia / Dystant Galaxy)
TypeSubscription Recurring
Description

Direct-to-consumer subscription for the Beats Medical Dyspraxia app (Dystant Galaxy). Offers a 'Base Level' free trial program followed by paid program packages for Gross Motor Galaxy, Fine Motor Meteor, Speech Station, or a combined Program Package. Available on iOS and Android app stores.

beatsmedical.com
3Pharma Partnership — White-Label / Co-Branded Platform Licensing
TypeLicensing Royalties
Description

Beats Medical deploys its Colbolt platform in white-labeled or co-branded solutions embedded into pharmaceutical company clinical pipelines, from pre-clinical through commercialization. Revenue derives from licensing the platform for use in clinical trials (assessment-only or full DTx), with partners including Top 10 Global Pharma companies. This is the primary B2B revenue stream targeting precision digital assessments and digital therapeutic solutions for CNS and rare conditions.

beatsmedical.com
4Digital Consulting Services
TypeProfessional Services
Description

Beats Medical provides strategic digital consulting to pharmaceutical companies to define digital strategy for evidence generation, covering the Understand-Decide-Define framework. Deliverables include research, business case development, and a detailed digital product deployment roadmap including system architecture, data models, and risk management. Consulting supports adoption of the Colbolt platform for clinical trials and post-market surveillance.

beatsmedical.com
5Insurance Reimbursement (Vhi Partnership)
TypeManaged Services
Description

The Beats Medical Dyspraxia app is directly reimbursed by Ireland's largest private health insurer, Vhi, providing coverage for more than 1.2 million customers. This creates a third-party payer revenue stream where insurers reimburse the digital therapeutic, expanding beyond direct consumer payments.

beatsmedical.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Marketing or Sales, Operations, Others
Pricing details3 tiers
114-Day Free Trial — no cost for 14 days
ModelFreemiumBilling cadencePay-as-you-go
Notes

14-day free trial of the Parkinson's app with access to all daily therapies (walking metronome, speech exercises, dexterity exercises), feedback and routine recommendations, and dedicated support team contact. After 14 days, converts to a paid subscription unless cancelled.

beatsmedical.com
2Monthly Subscription — €30.40/month (daily charge of €1.00)
ModelSubscriptionBilling cadenceMonthly
Notes

Monthly commitment at €30.40/month, billed daily at €1.00/day. Paid by direct debit. Includes daily tailored therapies (metronome, speech, dexterity), medication calendar reminders, monthly progress reports, and dedicated support. Annual renewal by default unless opted out.

beatsmedical.com
3Annual Subscription — €330/year (€27.50/month effective)
ModelSubscriptionBilling cadenceAnnual
Notes

One-year subscription at €330/year (effective €27.50/month, cheaper than monthly). Includes all monthly benefits plus exclusive Beats Medical Starter Pack (symptom diary, user guide, dexterity putty ball, tremor-friendly gummy stylus, voucher for annual online consultation) and free delivery. Hassle-free once-off payment.

beatsmedical.com
GTM typeB2B and B2C
B2B and B2C
Offering typeSoftware
Software
Brand1 of 4 records shown
1Colbolt
Description

Intelligent DTx platform with patented AI and ML technology powering objective assessments and tailored digital therapeutics through smartphone applications.

beatsmedical.com
+3 more records
Core offering1 text field

Beats Medical develops the Colbolt© intelligent Digital Therapeutics platform, an AI/ML-powered smartphone-based system that delivers objective digital assessments and tailored therapies for CNS and rare conditions without requiring additional hardware. The company sells B2B licensing of the Colbolt platform to pharmaceutical companies for use in clinical trials (white-label or co-branded) and offers B2C subscription consumer apps for Parkinson's patients and children with Dyspraxia, complemented by digital consulting services and observational/clinical trial solutions.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 8 values shown
  • 5-fold increase in data precision vs. traditional methods
+7 more records
Product overview1 text field

Beats Medical offers a unified platform architecture centered on the Colbolt© intelligent DTx platform, which powers objective digital assessments and tailored digital therapies for CNS and rare conditions. The product portfolio includes the core Colbolt© Platform for pharmaceutical partners, supplemented by consumer-facing therapy applications: the Parkinson's App addressing mobility, speech and dexterity symptoms; the Dystant Galaxy app for children's dyspraxia; the Wonders Cape wellbeing app for children; and the Branches app for clinical research participants. Service offerings encompass Digital Consulting, Observational Study Solutions, Clinical Trial Solutions, and Data Insights—all leveraging the Colbolt© technology to deliver AI-powered assessments via smartphone with no additional hardware required.

Product and service4 records
1Colbolt© Platform
CategoryDigital Therapeutics Platform (Core Technology)
Description

Beats Medical's intelligent Digital Therapeutics platform based on patented AI and ML processes that delivers objective digital assessments and tailored therapies across multiple CNS and rare conditions. Requires no additional hardware and deploys via smartphone applications (iOS and Android). Powers both consumer apps and white-label/co-branded pharma clinical trial deployments.

2Beats Medical Parkinson's Therapy App
CategoryConsumer Digital Therapeutic App
Description

Award-winning prescription-only digital therapy app for individuals diagnosed with Parkinson's Disease. Addresses Mobility (tailored walking metronome therapy), Speech (language exercises with real-time feedback on volume and intensity), and Dexterity (hand exercises) symptoms. Available for home use via monthly (€30.40/month) or annual (€330/year) subscription with 14-day free trial, excluding the US.

3Dystant Galaxy (Dyspraxia App)
CategoryConsumer Digital Therapeutic App
Description

Interactive therapy app for children aged 5-14 with Dyspraxia or Developmental Coordination Disorder. Delivers daily exercises through space-themed gamified activities targeting gross motor (Gross Motor Galaxy), fine motor (Fine Motor Meteor), speech and communication (Speech Station) skills, with a combined Program Package available. Available on iOS and Android with base level free trial and paid program packages.

4Wonders Cape App
Scale indicator13 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
1Top 10 Global Pharmaceutical Companies
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Beats Medical partners with leading pharmaceutical companies to improve real-world data and evidence collection, from pre-clinical stages to drug commercialization. The company deploys its Colbolt platform as white-labeled or co-branded solutions embedded in pharma pipelines, delivering precision digital assessments to enhance R&D activities and providing tailored digital therapies that drive long-term behavioral change. Over 85% of CNS drug trials fail due to insufficient outcome measures — Beats Medical addresses this core challenge with objective digital assessments.

beatsmedical.com
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Vhi, Ireland's largest private health insurer, partnered with Beats Medical to provide direct reimbursement coverage for the Dyspraxia app for children. The partnership covers over 1.2 million Vhi customers. This is a flagship insurance reimbursement model for digital therapeutics in Ireland. Vhi stated: 'Technology like this can significantly improve condition management for our customers' lives because it's more convenient, engaging, and in this case, it may even be a game-changer.'

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Beats Medical partnered with SPEM on a usability study deploying the Colbolt Platform to digitize mobility assessments for Multiple Sclerosis patients. The collaboration produced a whitepaper titled 'Reimagining Mobility Assessments in MS,' reflecting a shared commitment to driving breakthroughs informed by patient voices, experiences, and insights. SPEM's endorsement validates the platform's applicability across a broad range of CNS conditions beyond Parkinson's.

Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Trinity College Dublin conducted research on Beats Medical's digitised 2-Minute Walk Test (2MWT), demonstrating a Pearson correlation of r=0.98 versus gold-standard clinician-administered assessment. This independent academic validation provides rigorous clinical evidence for the platform's accuracy and reliability in measuring mobility.

Strategic tierSupportingTypeOthers
Description

OurMobileHealth, a panel of independent digital health experts, conducted a detailed analysis of the Beats Medical app across multiple areas. Beats Medical scored 100% in Regulatory Approval, Security, Effectiveness, Usability, and Technical Stability, achieving an overall average of 98%. This independent validation enhances credibility with healthcare providers and insurers.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Prescription digital therapeutics company (EndeavorRx) operating in the same regulated DTx category as Beats Medical's Parkinson's app. Targets neurological conditions with software-based therapies and pursues pharma partnerships, directly competing for payer and prescriber attention.

TypeBroad incumbent
Description

Large clinical trial technology provider offering eCOA, ePRO, and digital endpoint solutions to pharma across all phases. Comparable to Beats Medical's clinical trial solutions business, though Signant is a broader incumbent serving multiple therapeutic areas at greater scale.

TypeDirect peer
Description

Digital therapeutics company developing software-based therapy companions, particularly in oncology and chronic disease. Comparable to Beats Medical in prescription DTx positioning and pharma co-development models.

TypeDirect peer
Description

Prescription digital therapeutics company developing software-based treatments across CNS indications, including major pharma collaborations. Overlaps with Beats Medical's Colbolt platform in CNS conditions, prescription DTx positioning, and pharma commercialization partnerships.

5CureApp
TypeEmerging player
Description

Japan-based prescription digital therapeutics company developing regulator-approved software therapies across multiple indications. Comparable to Beats Medical in regulated, prescription DTx positioning and pharma partnership model, primarily regional to Japan.

TypeDirect peer
Description

Digital biomarker company providing wearable and smartphone-based assessments for clinical trials in CNS and other therapeutic areas. Direct overlap with Beats Medical's Colbolt platform in pharma clinical trial digital endpoints and decentralized assessment.

TypeDirect peer
Description

Digital therapeutics company focused on neurologic conditions, leveraging sensor-based gait and walking interventions similar to Beats Medical's gross-motor metronome therapy. Competes in the same neurological DTx category with prescription-grade positioning.

TypeEmerging player
Description

Neurological digital therapeutics and digital biomarker company building AI-driven therapies for brain recovery and CNS disorders. Comparable to Beats Medical in CNS focus and pharma-adjacent go-to-market, though with a hardware-tilted platform.

9Biofourmis
TypeBroad incumbent
Description

Decentralized clinical trial and remote patient monitoring platform serving pharma across multiple therapeutic areas. Comparable to Beats Medical's Colbolt platform in DCT and clinical research deployment, though Biofourmis is broader in scope and condition coverage.

TypeEmerging player
Description

Decentralized clinical trial operating system enabling remote participation in clinical research. Overlaps with Beats Medical's Branches app and Colbolt-powered clinical trial deployments, though Science 37 is a broader platform versus Beats Medical's condition-specific assessments.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration4 records

Each record includes

Title, Type, Description, Source

AI capability7 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Beats Medical

Digital Therapeuticsbeatsmedical.com

Beats Medical develops the Colbolt© AI/ML digital therapeutics platform that delivers objective assessments and tailored therapies via smartphone apps for CNS and rare conditions, serving pharmaceutical companies (clinical trials), individual Parkinson's and Dyspraxia patients via subscription apps, and insurers through Vhi reimbursement.

What Beats Medical does

Beats Medical Limited (trading as Beats Medical, incorporated as Beats Therapeutics Limited, Ireland company number 619940) is a Dublin-based digital therapeutics company founded in 2013 by chartered physiotherapist Dr Ciara Clancy. The company develops the Colbolt© platform, a patented AI/ML-powered DTx architecture that delivers objective digital assessments and tailored therapies via smartphone applications for central nervous system (CNS) and rare conditions, using built-in sensors (accelerometer, gyroscope, microphone) without additional hardware. The product portfolio spans four consumer-facing apps — the prescription-only Parkinson's app (mobility, speech, dexterity), Dystant Galaxy for pediatric Dyspraxia, Wonders Cape for child wellbeing, and the Branches clinical research app — plus B2B services including digital consulting, observational study solutions, clinical trial solutions, and data insights powered by Colbolt.

The company operates a dual-track go-to-market: (1) B2B pharma, where Colbolt is white-labeled or co-branded into the clinical pipelines of Top 10 Global Pharma companies from pre-clinical through commercialization; and (2) direct-to-consumer subscriptions (€30.40/month or €330/year) via iOS and Android app stores with a 14-day free trial, supplemented by insurance reimbursement through Vhi (Ireland's largest private health insurer, covering 1.2M+ customers for the Dyspraxia app). Revenue streams comprise consumer subscription recurring fees, pharma platform licensing and royalties, digital consulting professional services, and managed insurance reimbursement. Beats Medical is ISO 13485 certified, employs 1-10 people, and operates from Sandyford, Dublin, with commercial users across 30+ countries.

Beats Medical firmographics

Firmographics
Name
Beats Medical
Legal name
Beats Therapeutics Limited
Website
https://beatsmedical.com
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
11–50 employees
Short description
Beats Medical develops the Colbolt© AI/ML digital therapeutics platform that delivers objective assessments and tailored therapies via smartphone apps for CNS and rare conditions, serving pharmaceutical companies (clinical trials), individual Parkinson's and Dyspraxia patients via subscription apps, and insurers through Vhi reimbursement.
Ownership category
akta.pro rank

Beats Medical industry classification

Industry
Product category
Digital Therapeutics
NAICS
Other Scientific and Technical Consulting Services (54169), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Scientific Research and Development Services (5417)
SIC
Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLACANAH
Therapeutic Companion Apps (Drug-Device-Digital Combination)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLACAOAL
Decentralized/Hybrid Trial Enablement (DCT) Platforms
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Trials & Research Informatics (eCOA/ePRO/EDC)
SECONDARYHLAGAJAM
Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)

Keywords

  • Digital therapeutics
  • Clinical trial technology
  • Parkinson's disease apps
  • Digital biomarkers
  • Mobile health assessments

Where Beats Medical is headquartered

Location

Headquarters

HQ city
Dublin
HQ country
Ireland
HQ region
Europe

Offices1 record

Markets served

Beats Medical business model

Business model
GTM type
B2B and B2C
Offering type
Software
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations, Others

Revenue model

  1. Consumer App Subscriptions (Parkinson's): Direct-to-consumer subscription for the Beats Medical Parkinson's Therapy app. Two tiers: Monthly subscription at €30.40/month (daily charge of €1.00) paid by direct debit; Annual subscription at €330/year (€27.50/month equivalent). Subscriptions auto-renew annually. 14-day free trial available for conversion. Services include daily tailored walking metronome therapy, speech exercises, dexterity exercises, calendar medication reminders, and monthly progress reports. The app is prescription-only and intended for home use.
  2. Consumer App Subscriptions (Dyspraxia / Dystant Galaxy): Direct-to-consumer subscription for the Beats Medical Dyspraxia app (Dystant Galaxy). Offers a 'Base Level' free trial program followed by paid program packages for Gross Motor Galaxy, Fine Motor Meteor, Speech Station, or a combined Program Package. Available on iOS and Android app stores.
  3. Pharma Partnership — White-Label / Co-Branded Platform Licensing: Beats Medical deploys its Colbolt platform in white-labeled or co-branded solutions embedded into pharmaceutical company clinical pipelines, from pre-clinical through commercialization. Revenue derives from licensing the platform for use in clinical trials (assessment-only or full DTx), with partners including Top 10 Global Pharma companies. This is the primary B2B revenue stream targeting precision digital assessments and digital therapeutic solutions for CNS and rare conditions.
  4. Digital Consulting Services: Beats Medical provides strategic digital consulting to pharmaceutical companies to define digital strategy for evidence generation, covering the Understand-Decide-Define framework. Deliverables include research, business case development, and a detailed digital product deployment roadmap including system architecture, data models, and risk management. Consulting supports adoption of the Colbolt platform for clinical trials and post-market surveillance.
  5. Insurance Reimbursement (Vhi Partnership): The Beats Medical Dyspraxia app is directly reimbursed by Ireland's largest private health insurer, Vhi, providing coverage for more than 1.2 million customers. This creates a third-party payer revenue stream where insurers reimburse the digital therapeutic, expanding beyond direct consumer payments.

Pricing tiers

ModelBillingPrice
FreemiumPay-as-you-go14-Day Free Trial — no cost for 14 days
SubscriptionMonthlyMonthly Subscription — €30.40/month (daily charge of €1.00)
SubscriptionAnnualAnnual Subscription — €330/year (€27.50/month effective)

Go-to-market motion3 records

Distribution channels4 records

Marketing channels6 records

Beats Medical product offering

Product offering

Core offering

Beats Medical develops the Colbolt© intelligent Digital Therapeutics platform, an AI/ML-powered smartphone-based system that delivers objective digital assessments and tailored therapies for CNS and rare conditions without requiring additional hardware. The company sells B2B licensing of the Colbolt platform to pharmaceutical companies for use in clinical trials (white-label or co-branded) and offers B2C subscription consumer apps for Parkinson's patients and children with Dyspraxia, complemented by digital consulting services and observational/clinical trial solutions.

Product overview

Beats Medical offers a unified platform architecture centered on the Colbolt© intelligent DTx platform, which powers objective digital assessments and tailored digital therapies for CNS and rare conditions. The product portfolio includes the core Colbolt© Platform for pharmaceutical partners, supplemented by consumer-facing therapy applications: the Parkinson's App addressing mobility, speech and dexterity symptoms; the Dystant Galaxy app for children's dyspraxia; the Wonders Cape wellbeing app for children; and the Branches app for clinical research participants. Service offerings encompass Digital Consulting, Observational Study Solutions, Clinical Trial Solutions, and Data Insights—all leveraging the Colbolt© technology to deliver AI-powered assessments via smartphone with no additional hardware required.

Differentiator

Problem solved

Functional benefit

Brands

  • Colbolt: Intelligent DTx platform with patented AI and ML technology powering objective assessments and tailored digital therapeutics through smartphone applications.
  • Dystant Galaxy
  • Wonders Cape
  • Branches

Products and services

  • Colbolt© Platform Beats Medical's intelligent Digital Therapeutics platform based on patented AI and ML processes that delivers objective digital assessments and tailored therapies across multiple CNS and rare conditions. Requires no additional hardware and deploys via smartphone applications (iOS and Android). Powers both consumer apps and white-label/co-branded pharma clinical trial deployments.
  • Beats Medical Parkinson's Therapy App Award-winning prescription-only digital therapy app for individuals diagnosed with Parkinson's Disease. Addresses Mobility (tailored walking metronome therapy), Speech (language exercises with real-time feedback on volume and intensity), and Dexterity (hand exercises) symptoms. Available for home use via monthly (€30.40/month) or annual (€330/year) subscription with 14-day free trial, excluding the US.
  • Dystant Galaxy (Dyspraxia App) Interactive therapy app for children aged 5-14 with Dyspraxia or Developmental Coordination Disorder. Delivers daily exercises through space-themed gamified activities targeting gross motor (Gross Motor Galaxy), fine motor (Fine Motor Meteor), speech and communication (Speech Station) skills, with a combined Program Package available. Available on iOS and Android with base level free trial and paid program packages.
  • Wonders Cape App

Quantifiable outcome

  • 5-fold increase in data precision vs. traditional methods
  • +7 more outcomes

Companies that use Beats Medical

Customer profile

Named customers6 records

Ideal customer profiles3 records

Beats Medical technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration4 records

AI capability7 records

Feature7 records

Beats Medical partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and supporting.

  • Top 10 Global Pharmaceutical CompaniescoreStrategic or Co-development PartnerBeats Medical partners with leading pharmaceutical companies to improve real-world data and evidence collection, from pre-clinical stages to drug commercialization. The company deploys its Colbolt platform as white-labeled or co-branded solutions embedded in pharma pipelines, delivering precision digital assessments to enhance R&D activities and providing tailored digital therapies that drive long-term behavioral change. Over 85% of CNS drug trials fail due to insufficient outcome measures — Beats Medical addresses this core challenge with objective digital assessments.
  • VhicoreChannel Partner/ Reseller/ DistributorVhi, Ireland's largest private health insurer, partnered with Beats Medical to provide direct reimbursement coverage for the Dyspraxia app for children. The partnership covers over 1.2 million Vhi customers. This is a flagship insurance reimbursement model for digital therapeutics in Ireland. Vhi stated: 'Technology like this can significantly improve condition management for our customers' lives because it's more convenient, engaging, and in this case, it may even be a game-changer.'
  • Portuguese MS Society (SPEM)coreStrategic or Co-development PartnerBeats Medical partnered with SPEM on a usability study deploying the Colbolt Platform to digitize mobility assessments for Multiple Sclerosis patients. The collaboration produced a whitepaper titled 'Reimagining Mobility Assessments in MS,' reflecting a shared commitment to driving breakthroughs informed by patient voices, experiences, and insights. SPEM's endorsement validates the platform's applicability across a broad range of CNS conditions beyond Parkinson's.
  • Trinity College DublinsupportingStrategic or Co-development PartnerTrinity College Dublin conducted research on Beats Medical's digitised 2-Minute Walk Test (2MWT), demonstrating a Pearson correlation of r=0.98 versus gold-standard clinician-administered assessment. This independent academic validation provides rigorous clinical evidence for the platform's accuracy and reliability in measuring mobility.
  • OurMobileHealthsupportingOthersOurMobileHealth, a panel of independent digital health experts, conducted a detailed analysis of the Beats Medical app across multiple areas. Beats Medical scored 100% in Regulatory Approval, Security, Effectiveness, Usability, and Technical Stability, achieving an overall average of 98%. This independent validation enhances credibility with healthcare providers and insurers.

Scale indicators13 records

Recent moves6 records

Expansion highlights5 records

Beats Medical competitors and assessment

Company assessment

Direct peers

  • Akili Interactive: Prescription digital therapeutics company (EndeavorRx) operating in the same regulated DTx category as Beats Medical's Parkinson's app. Targets neurological conditions with software-based therapies and pursues pharma partnerships, directly competing for payer and prescriber attention.
  • Voluntis (Aptar Digital Health): Digital therapeutics company developing software-based therapy companions, particularly in oncology and chronic disease. Comparable to Beats Medical in prescription DTx positioning and pharma co-development models.
  • Click Therapeutics: Prescription digital therapeutics company developing software-based treatments across CNS indications, including major pharma collaborations. Overlaps with Beats Medical's Colbolt platform in CNS conditions, prescription DTx positioning, and pharma commercialization partnerships.
  • Koneksa Health: Digital biomarker company providing wearable and smartphone-based assessments for clinical trials in CNS and other therapeutic areas. Direct overlap with Beats Medical's Colbolt platform in pharma clinical trial digital endpoints and decentralized assessment.
  • MedRhythms: Digital therapeutics company focused on neurologic conditions, leveraging sensor-based gait and walking interventions similar to Beats Medical's gross-motor metronome therapy. Competes in the same neurological DTx category with prescription-grade positioning.

Broad incumbents

  • Signant Health: Large clinical trial technology provider offering eCOA, ePRO, and digital endpoint solutions to pharma across all phases. Comparable to Beats Medical's clinical trial solutions business, though Signant is a broader incumbent serving multiple therapeutic areas at greater scale.
  • Biofourmis: Decentralized clinical trial and remote patient monitoring platform serving pharma across multiple therapeutic areas. Comparable to Beats Medical's Colbolt platform in DCT and clinical research deployment, though Biofourmis is broader in scope and condition coverage.

Emerging players

  • CureApp: Japan-based prescription digital therapeutics company developing regulator-approved software therapies across multiple indications. Comparable to Beats Medical in regulated, prescription DTx positioning and pharma partnership model, primarily regional to Japan.
  • MindMaze: Neurological digital therapeutics and digital biomarker company building AI-driven therapies for brain recovery and CNS disorders. Comparable to Beats Medical in CNS focus and pharma-adjacent go-to-market, though with a hardware-tilted platform.
  • Science 37: Decentralized clinical trial operating system enabling remote participation in clinical research. Overlaps with Beats Medical's Branches app and Colbolt-powered clinical trial deployments, though Science 37 is a broader platform versus Beats Medical's condition-specific assessments.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Beats Medical social profiles

Digital presence

Beats Medical compliance and trust

Trust signal

Compliance1 record

Beats Medical financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Beats Medical leadership team

Management profile

Number of profiles

Profiles4 records

Beats Medical funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Beats Medical M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Beats Medical

What does Beats Medical do?

Beats Medical develops the Colbolt© intelligent Digital Therapeutics platform, an AI/ML-powered smartphone-based system that delivers objective digital assessments and tailored therapies for CNS and rare conditions without requiring additional hardware. The company sells B2B licensing of the Colbolt platform to pharmaceutical companies for use in clinical trials (white-label or co-branded) and offers B2C subscription consumer apps for Parkinson's patients and children with Dyspraxia, complemented by digital consulting services and observational/clinical trial solutions.

Is Beats Medical a public or private company?

Beats Medical is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Beats Medical founded?

Beats Medical was founded in 2013. It employs 11 to 50 people.

Where is Beats Medical based?

Beats Medical is headquartered in Dublin, Ireland, in the Europe region.

How does Beats Medical make money?

Five revenue lines are on record. Consumer App Subscriptions (Parkinson's) is the primary driver. The others are consumer App Subscriptions (Dyspraxia / Dystant Galaxy), pharma Partnership — White-Label / Co-Branded Platform Licensing, digital Consulting Services and insurance Reimbursement (Vhi Partnership).

Who are Beats Medical's main competitors?

Direct peers on record are Akili Interactive, Voluntis (Aptar Digital Health), Click Therapeutics, Koneksa Health and MedRhythms. Broad incumbents are Signant Health and Biofourmis. Emerging players are CureApp, MindMaze and Science 37.

Does Beats Medical have an API?

No public API is recorded for Beats Medical.

What industry is Beats Medical in?

Beats Medical's product category is Digital Therapeutics. Its primary akta.pro industry code is HLACANAH, Therapeutic Companion Apps (Drug-Device-Digital Combination), with a secondary code of HLACAOAL, Decentralized/Hybrid Trial Enablement (DCT) Platforms. Its NAICS code is 54169 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals